Sandoz Tilray Agreement

The agreement originated in Canada, the second country in the world and the only G7 member to legalize recreational marijuana. Through Sandoz, a subsidiary of Novartis, Tilray signed a similar agreement in 2017 for the distribution and sale of cannabis-based medical products – an agreement that resulted in this much larger agreement that extends the agreement to some 35 countries around the world that have medical cannabis laws. a figure that Kennedy says will likely increase in the future. Tilray, a global pioneer in medical cannabis, has products in twelve countries and branches in Australia and New Zealand, Canada, Germany, Latin America and Portugal. This agreement builds on Tilray`s innovative track record as a company committed to providing pharmaceutical-grade medical cannabis products to patients in need. Tilray was the first licensed medical cannabis producer in North America to achieve the current Good Manufacturing Practice (CGMP) certification in accordance with European Medicines Agency (EMA) standards. “This agreement marks an important step in enabling patients in distress around the world to have access to safe, GMP-certified medical cannabis,” said Brendan Kennedy, CEO of Tilray, noting that there are now 35 countries around the world that have legalized medical cannabis and there could be 60 or 70 within two to three years. As part of the deal, Tilray will be able to use Sandoz`s muscular global distribution channels to pave the way for the marijuana producer to introduce medical devices where the law allows, Kennedy said. Tilray said it has an exclusive agreement with Novartis, which cannot work with another pot company, and Tilray cannot enter into a pact with another pharmaceutical company on flammable products. “This agreement marks an important step in providing distressed patients around the world with access to safe, GMP-certified medical cannabis,” said Brendan Kennedy, Chief Executive Officer of Tilray. “Tilray is a global company and we are pleased to build on the success and dynamism of our existing agreement with Sandoz Canada by leveraging our global partnership.

Sandoz AG will be a valuable partner if we work together to improve access to high-quality cannabis products in countries around the world. NANAIMO, British Columbia (BUSINESS WIRE)-Tilray Canada Ltd., a subsidiary of Tilray Inc. (NASDAQ: TLRY), a global pioneer in the production, research and distribution of medical cannabis, today announced that it has entered into a comprehensive framework agreement (“Framework Agreement”) to cooperate with Sandoz AG, a global leader in generic and biosimilars and part of the Novartis Group. increase the availability of high-quality medical cannabis products worldwide. Media: Chrissy Roebuck, news@tilray.com, 1-833-206-8161Invesstants: Katie Turner, +1-646-277-1228, Katie.turner@icrinc.com kennedy also said that companies will work together to develop new products, and have several that focus on the defined dosage…

This entry was posted in Uncategorized. Bookmark the permalink.